Breast cancer will lead anti-neoplastic pharmaceutical agents sales through 2036 with a 23.6% share of the type of cancer segment. The market value is placed at USD 158.2 billion in 2026 and is forecast to reach USD 441.3 billion by 2036 across key growth regions including China, India, and the USA.